Tafluprost and analogs thereof for reducing fat
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07C-059/46
A61K-031/5575
A61K-009/00
A61K-009/06
출원번호
US-0363923
(2012-12-19)
등록번호
US-9180130
(2015-11-10)
국제출원번호
PCT/US2012/070581
(2012-12-19)
국제공개번호
WO2013/096429
(2013-06-27)
발명자
/ 주소
Kalayoglu, Murat V.
Singer, Michael S.
출원인 / 주소
Topokine Therapeutics, Inc.
대리인 / 주소
Wolf, Greenfield & Sacks, P.C.
인용정보
피인용 횟수 :
7인용 특허 :
60
초록▼
Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug th
Provided are methods of reducing body fat in a subject, comprising locally (e.g., topically) administering one or more compounds of the Formula (I) and/or (V): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein X is —OR1, —SR2, or —NR3R4, and R1, R2, R3, R4, R5, R6, R7, R7′, Z, Y, n, y, and x, are as defined herein.
대표청구항▼
1. A method for reducing fat in a body of a subject in need thereof, the method comprising injecting into a fat deposit a compound of the Formula (II): or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is hydrogen or C1-C6 alkyl. 2. The method of claim 1, wherein the fat dep
1. A method for reducing fat in a body of a subject in need thereof, the method comprising injecting into a fat deposit a compound of the Formula (II): or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R1 is hydrogen or C1-C6 alkyl. 2. The method of claim 1, wherein the fat deposit comprises a tumor. 3. The method of claim 1, wherein the tumor is a lipoma. 4. The method of claim 1, wherein the fat deposit is excess body fat that is a side effect of a medication. 5. The method of claim 4, wherein the medication is selected from the group consisting of a corticosteroid, an anti-retroviral, an antidepressant, an oral contraceptive, and insulin. 6. The method of claim 1, wherein the composition is a sterile injectable preparation selected from the group consisting of a sterile solution, sterile suspension, and sterile emulsion. 7. The method of claim 6, wherein the sterile injectable preparation is sterilized by filtration through a bacterial-retaining filter. 8. The method of claim 1, wherein R1 is hydrogen. 9. The method of claim 1, wherein R1 is C1-C4 alkyl. 10. The method of claim 1, wherein R1 is methyl, ethyl, isopropyl, n-propyl, n-butyl, tert-butyl, isobutyl, or sec-butyl. 11. The method of claim 1, wherein the compound is: 12. The method of claim 1, wherein the fat deposit comprises orbital fat. 13. The method of claim 1, wherein the fat deposit is localized to the abdomen, chest, breast, buttocks, hips, thighs, legs, knees, arms, chin, neck, or face. 14. The method of claim 1, wherein the subject suffers from obesity. 15. The method of claim 1, wherein the subject suffers from a condition selected from the group consisting of human immunodeficiency virus lipodystrophy, acquired lipodystrophy, and familial lipodystrophy. 16. The method of claim 1, wherein the subject suffers from gynecomastia. 17. The method of claim 1, wherein the injecting is subcutaneous. 18. The method of claim 1, wherein the injecting is intralesional. 19. The method of claim 1, wherein the composition comprises one or more pharmaceutically acceptable excipients, and the concentration of the compound in the composition is between 0.001% and 1% (w/w) or (w/v), inclusive. 20. The method of claim 1, wherein the injecting reduces the volume, size, mass, bulk, and/or density of the fat deposit.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (60)
Feng Zixia ; Hellberg Mark R., 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension.
Ling, Kah-Hiing John; Yang, Wu; Ni, Jinsong; Yuan, Haiqing; Tang-Liu, Diane D. S., 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma.
Hubbard Vance M. (Bedford) Brunson Welton K. (Bedford) Saied V. C. (Wichita Falls TX), Apparatus and method for raising a skin wheal and anesthetizing skin.
Woodward David F. (El Toro CA) Andrews Steven W. (Rancho Santa Marguerita CA) Burk Robert M. (Irvine CA) Garst Michael E. (Newport Beach CA), Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Lilley Stephen J. (Sawston GBX) Taylor Hugh F. (Sawston GBX) Theobald David R. (Huntingdon GBX) Carlson Craig J. (Andover MA) Rosen David I. (Arlington MA) Johnson Thomas R. (Milford NH), Medical injection system and method, gas spring thereof and launching device using gas spring.
Tennenbaum, Tamar; Braiman-Wiksman, Liora; Solominik, Inessa; Meir, Michal, Method and compositions for prevention and treatment of diabetic and aged skin.
Pintor, Jesus J.; Peral, Maria A.; Peterson, Ward M.; Plourde, Jr., Robert; Brown, Edward G.; Yerxa, Benjamin R., Method for reducing intraocular pressure using indole derivatives.
McKinnon ; Jr. Charles N. (Laguna Niguel CA) Peterson Steven F. (West Linn OR) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection device.
Peterson Steven F. (West Linn OR) McKinnon ; Jr. Charles N. (Laguna Niguel CA) Smith Paul E. (Tualatin OR) Nakagawa Takaaki (Tigard OR) Bartholomew Victor L. (Tigard OR), Needleless hypodermic injection methods and device.
David F. Woodward ; Steven W. Andrews ; Robert M. Burk ; Michael E. Garst, Non-acidic cyclopentane heptanoic acid,2-cycloalkyl or arylalkyl derivatives as therapeutic agents.
Klimko Peter G. ; Bishop John E. ; Sallee Verney L. ; Zinke Paul W., Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension.
Hellberg, Mark R.; Nixon, Jon C., Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.